Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion–Positive Non–Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial

Ying Cheng; Dingzhi Huang; Jianying Zhou; Chengzhi Zhou; Yuping Sun; Lin Wu; Ye Guo; Shao Jingxin; Wanli Zhang; Shun Lu

Journal ArticleOPEN ACCESS

Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion–Positive Non–Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial

Cheng Y
Huang D
Zhou J
et al.

JCO Precision Oncology (2023) (7)

DOI: 10.1200/po.22.00708

7Citations

10Readers

Abstract

Selpercatinib had intracranial activity in Chinese patients with brain metastases from RET-altered NSCLC.

Cite

CITATION STYLE

APA

Cheng, Y., Huang, D., Zhou, J., Zhou, C., Sun, Y., Wu, L., … Lu, S. (2023). Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion–Positive Non–Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial. JCO Precision Oncology, (7). https://doi.org/10.1200/po.22.00708

Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion–Positive Non–Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial

Abstract

Cite

Register to see more suggestions